Charter Renewal of the Advisory Committee on Blood and Tissue Safety and Availability, 70184-70185 [2020-24404]

Download as PDF 70184 Federal Register / Vol. 85, No. 214 / Wednesday, November 4, 2020 / Notices tuberculin testing of the herds. In addition, the regulations in part 1210 require that dairy farmers and plants maintain pasteurization records (§ 1210.15) and that each container of milk or cream imported into the United States bear a tag with the product type, permit number, and shipper’s name and address (§ 1210.22). Section 1210.20 requires that an application for a permit to ship or transport milk or cream into the United States be made by the actual shipper. Section 1210.23 allows permits to be granted based on certificates from accredited officials. Description of Respondents: Respondents include foreign dairy farms and plants engaged in transporting milk and/or cream into the United States. Respondents are from the private sector (for-profit businesses). We estimate the burden of this collection of information as follows: TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1 Number of respondents Number of responses per respondent Total annual responses 1 1 1 1 200 1 1 1 200 1 1 1 1.5 .......................... 0.5 (30 minutes) ..... 0.5 (30 minutes) ..... 2 ............................. 300 0.5 0.5 2 1 1 1 0.5 (30 minutes) ..... 0.5 1210.23 ...... 1996/Farm Inspection Report ............................. 1995/Report of Physical Examination of Cows .. 1994/Report of Tuberculin Tests of Cattle ......... 1997/Score Card for Sanitation Inspections of Milk Plants. 1993/Application for Permit to Ship or Transport Milk and/or Cream into United States. 1815/Certificate/Transmittal for an Application ... 1 1 1 0.5 (30 minutes) ..... 0.5 Total .... ............................................................................. .................... ........................ .................... ................................ 304 21 CFR section 1210.11 1210.12 1210.13 1210.14 ...... ...... ...... ...... 1210.20 ...... 1 There Form FDA No. Average burden per response Total hours are no capital costs or operating and maintenance costs associated with this collection of information. TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1 Number of recordkeepers 21 CFR section; activity 1210.15 Pasteurization; Equipment, and Methods ......... khammond on DSKJM1Z7X2PROD with NOTICES 1 Number of records per recordkeeper 1 Total annual records 1 Average burden per recordkeeping 1 Total hours 0.05 (3 minutes) ..... 0.05 There are no capital costs or operating and maintenance costs associated with this collection of information. The Secretary of Health and Human Services has the discretion to allow Form FDA 1815, a duly certified statement signed by an accredited official of a foreign government, to be submitted in lieu of Forms FDA 1994 and 1995. In the past, Form FDA 1815 has been submitted in lieu of these forms. Because we have not received any Forms FDA 1994 or 1995 in the last 3 years, we assume no more than one will be submitted annually. No burden has been estimated for the tagging requirement in § 1210.22 because the information on the tag is either supplied by us (permit number) or is disclosed to third parties as a usual and customary part of the shipper’s normal business activities (type of product, shipper’s name and address). Under 5 CFR 1320.3(c)(2), the public disclosure of information originally supplied by the Federal Government to the recipient for the purpose of disclosure to the public is not subject to review by OMB under the PRA. Under 5 CFR 1320.3(b)(2)), the time, effort, and financial resources necessary to comply with a collection of information are excluded from the burden estimate if the reporting, recordkeeping, or disclosure activities needed to comply are usual and customary because they VerDate Sep<11>2014 18:16 Nov 03, 2020 Jkt 253001 would occur in the normal course of business activities. Based on a review of the information collection since our last OMB approval, we have decreased our burden estimate. The estimated number of respondents and hours per response are based on our experience with the import milk permit program and the average number of import milk permit holders over the past 3 years. However, we have not received any responses in the last 3 years; therefore, we estimate that one or fewer to be submitted annually. Although we have not received any responses in the last 3 years, we believe these information collection provisions should be extended to provide for the potential future need for a milk importer. Dated: October 30, 2020. Lauren K. Roth, Acting Principal Associate Commissioner for Policy. [FR Doc. 2020–24428 Filed 11–3–20; 8:45 am] BILLING CODE 4164–01–P PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES Charter Renewal of the Advisory Committee on Blood and Tissue Safety and Availability Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: The Department of Health and Human Services is hereby giving notice that the charter for the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) has been renewed. SUMMARY: Mr. James Berger, Designated Federal Officer for the ACBTSA, Senior Advisor for Blood and Tissue Policy, Office of the Assistant Secretary for Health, Department of Health and Human Services, 330 C Street SW, Suite L600, Washington, DC 20024. Phone: (202) 795–7608. Email: ACBTSA@hhs.gov. SUPPLEMENTARY INFORMATION: The ACBTSA is a non-discretionary federal advisory committee. The ACBTSA is authorized under 42 U.S.C. 217a, Section 222 of the Public Health Service FOR FURTHER INFORMATION CONTACT: E:\FR\FM\04NON1.SGM 04NON1 Federal Register / Vol. 85, No. 214 / Wednesday, November 4, 2020 / Notices (PHS) Act, as amended. The Committee is governed by the provisions of the Federal Advisory Committee Act (FACA), Public Law 92–463, as amended (5 U.S.C. App.), which sets forth standards for the formation and use of advisory committees. The ACBTSA advises, assists, consults with, and makes policy recommendations to the Secretary, through the Assistant Secretary for Health, regarding broad responsibilities related to the safety of blood, blood products, tissues, and organs. For solid organs and blood stem cells, the Committee’s work is limited to policy issues related to donor derived infectious disease complications of transplantation. To carry out its mission, the ACBTSA provides advice to the Secretary through the Assistant Secretary for Health on a range of policy issues which includes: (1) Identification of public health issues through surveillance of blood and tissue safety issues with national biovigilance data tools; (2) identification of public health issues that affect availability of blood, blood products, and tissues; (3) broad public health, ethical, and legal issues related to the safety of blood, blood products, and tissues; (4) the impact of various economic factors (e.g., product cost and supply) on safety and availability of blood, blood products, and tissues; (5) risk communications related to blood transfusion and tissue transplantation; and (6) identification of infectious disease transmission issues for blood, organs, blood stem cells and tissues. On October 9, 2020, the Secretary approved for the ACBTSA charter to be renewed. The new charter was effected and filed with the appropriate Congressional committees and the Library of Congress on October 9, 2020. Renewal of the Committee’s charter gives authorization for the Committee to continue to operate until October 9, 2022. khammond on DSKJM1Z7X2PROD with NOTICES A copy of the ACBTSA charter is available on the Committee’s website at https://www.hhs.gov/oidp/advisorycommittee/blood-tissue-safetyavailability/charter/. Dated: October 22, 2020. James J. Berger, DFO, Advisory Committee on Blood and Safety and Availability, Office of Infectious Disease and HIV/AIDS Policy. [FR Doc. 2020–24404 Filed 11–3–20; 8:45 am] BILLING CODE 4150–28–P VerDate Sep<11>2014 18:16 Nov 03, 2020 Jkt 253001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Solicitation of Nominations for Appointment to the Tick-Borne Disease Working Group; Extension of Nomination Period Office of Infectious Disease and HIV/AIDS Policy (OIDP), Office of the Assistant Secretary for Health (OASH), Office of the Secretary, Department of Health and Human Services. ACTION: Notice; extension of nomination period. AGENCY: The Office of the Assistant Secretary for Health published a document in the Federal Register on October 6, 2020 seeking nominations of non-federal public individuals who represent diverse scientific disciplines and views and are interested in being considered for appointment to the TickBorne Disease Working Group (TBDWG). Due to requests to extend the nomination period, this document is announcing a 30-day extension. The October 6 notice can be accessed at https://www.govinfo.gov/content/pkg/ FR-2020-10-06/pdf/2020-22062.pdf. DATES: To be assured consideration, nominations must be sent to the TBDWG email address at tickbornedisease@hhs.gov no later than 5:00 p.m. Eastern Standard Time on December 5, 2020. FOR FURTHER INFORMATION CONTACT: Mr. James Berger, (202) 795–7608; tickbornedisease@hhs.gov. SUMMARY: Dated: October 29, 2020. James Berger, Senior Advisor for Blood and Tissue Policy, Designated Federal Officer, HHS Tick-Borne Disease Working Group and the Advisory Committee on Blood and Tissue Safety and Availability, Office of the Assistant Secretary for Health. [FR Doc. 2020–24414 Filed 11–3–20; 8:45 am] BILLING CODE 4150–28–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Neurological Disorders and Stroke Council. The meeting will be open to the public as indicated below. Individuals PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 70185 who plan to participate and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Neurological Disorders and Stroke Council. Date: February 3–4, 2021. Open: February 03, 2021, 1:00 p.m. to 6:00 p.m. Agenda: Report by the Director, NINDS; Report by the Director, Division of Extramural Activities; and Administrative and Program Developments. Open session will be videocast from this link: https://videocast.nih.gov/. Closed: February 04, 2021, 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, NSC Building, 6001 Executive Boulevard, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Robert Finkelstein, Ph.D., Director of Extramural Research, National Institute of Neurological Disorders and Stroke, NIH, 6001 Executive Blvd., Suite 3309, MSC 9531, Bethesda, MD 20892, (301) 496–9248, finkelsr@ninds.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: www.ninds.nih.gov, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS) Dated: October 29, 2020. Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–24395 Filed 11–3–20; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\04NON1.SGM 04NON1

Agencies

DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 85, Number 214 (Wednesday, November 4, 2020)]
[Notices]
[Pages 70184-70185]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-24404]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Charter Renewal of the Advisory Committee on Blood and Tissue 
Safety and Availability

AGENCY: Office of the Assistant Secretary for Health, Office of the 
Secretary, Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of Health and Human Services is hereby giving 
notice that the charter for the Advisory Committee on Blood and Tissue 
Safety and Availability (ACBTSA) has been renewed.

FOR FURTHER INFORMATION CONTACT: Mr. James Berger, Designated Federal 
Officer for the ACBTSA, Senior Advisor for Blood and Tissue Policy, 
Office of the Assistant Secretary for Health, Department of Health and 
Human Services, 330 C Street SW, Suite L600, Washington, DC 20024. 
Phone: (202) 795-7608. Email: [email protected].

SUPPLEMENTARY INFORMATION: The ACBTSA is a non-discretionary federal 
advisory committee. The ACBTSA is authorized under 42 U.S.C. 217a, 
Section 222 of the Public Health Service

[[Page 70185]]

(PHS) Act, as amended. The Committee is governed by the provisions of 
the Federal Advisory Committee Act (FACA), Public Law 92-463, as 
amended (5 U.S.C. App.), which sets forth standards for the formation 
and use of advisory committees. The ACBTSA advises, assists, consults 
with, and makes policy recommendations to the Secretary, through the 
Assistant Secretary for Health, regarding broad responsibilities 
related to the safety of blood, blood products, tissues, and organs. 
For solid organs and blood stem cells, the Committee's work is limited 
to policy issues related to donor derived infectious disease 
complications of transplantation.
    To carry out its mission, the ACBTSA provides advice to the 
Secretary through the Assistant Secretary for Health on a range of 
policy issues which includes: (1) Identification of public health 
issues through surveillance of blood and tissue safety issues with 
national biovigilance data tools; (2) identification of public health 
issues that affect availability of blood, blood products, and tissues; 
(3) broad public health, ethical, and legal issues related to the 
safety of blood, blood products, and tissues; (4) the impact of various 
economic factors (e.g., product cost and supply) on safety and 
availability of blood, blood products, and tissues; (5) risk 
communications related to blood transfusion and tissue transplantation; 
and (6) identification of infectious disease transmission issues for 
blood, organs, blood stem cells and tissues.
    On October 9, 2020, the Secretary approved for the ACBTSA charter 
to be renewed. The new charter was effected and filed with the 
appropriate Congressional committees and the Library of Congress on 
October 9, 2020. Renewal of the Committee's charter gives authorization 
for the Committee to continue to operate until October 9, 2022.
    A copy of the ACBTSA charter is available on the Committee's 
website at https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/charter/.

    Dated: October 22, 2020.
James J. Berger,
DFO, Advisory Committee on Blood and Safety and Availability, Office of 
Infectious Disease and HIV/AIDS Policy.
[FR Doc. 2020-24404 Filed 11-3-20; 8:45 am]
BILLING CODE 4150-28-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.